Skip to main content

Advertisement

Table 1 IC30 and IC50 of five anti-cancer agents against YBC-2, YBC-3, NCI-N87, U-87 MG and SK-BR-3 cell lines

From: Correlation between HER-2/neu(erbB-2) expression level and therapeutic effect of combination treatment with HERCEPTIN and chemotherapeutic agents in gastric cancer cell lines

Anticancer agents Cell lines (IC30) μM
YBC-2 YBC-3 NCI-N87 SK-BR-3 U-87 MG
Herceptin 82.36 11.83 1326.72 0.02 289.09
Doxorubicin 0.6 0.76 0.01 0.03 0.07
Cisplatin 1.79 21 9.28 14.54 2.58
Paclitaxel 0.52 6.45 0.86 0.19 0.3
5-FU 33.11 0.22 4.11 148.75 5.51
Anticancer agents Cell lines (IC 50 ) μM
YBC-2 YBC-3 NCI-N87 SK-BR-3 U-87 MG
Doxorubicin 2.93 2.31 0.07 0.1 0.29
Cisplatin 4.51 30.73 45.86 5.65 20.63
Paclitaxel 1.24 9.61 1.49 0.42 0.79
5-FU 752.04 4.74 119.61 753.42 46.58